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Abstract. Colorectal cancers exhibit a high telomerase 
activity, usually correlated with the hypermethylation of the 
promoter of its hTERT catalytic subunit. Although telome-
rase is not expressed in normal tissue, certain proliferative 
somatic cells such as intestinal crypt cells have demonstrated 
telomerase activity. The aim of this study was to determine 
whether a correlation exists between telomerase activity, 
levels of hTERT methylation and telomere length in tumoral 
and normal colorectal tissues. Tumor, transitional and normal 
tissues were obtained from 11 patients with a colorectal 
cancer. After bisulfite modification of genomic DNA, hTERT 
promoter methylation was analyzed by methylation-sensitive 
single-strand conformation analysis (MS-SSCA). Telomerase 
activity and telomere length were measured by a fluorescent‑ 
telomeric repeat amplification protocol assay and by Southern 
blotting, respectively. A significant increase of hTERT methy‑
lation and telomerase activity, and a reduction of the mean 
telomere length were observed in the tumor tissues compared 
to the transitional and normal mucosa. In the transitional and 
normal mucosa, telomerase activity was significantly lower 
than that in tumor tissues, even with high levels of hTERT 
methylation. Nevertheless, hTERT promoter methylation was 
not linearly correlated to telomerase activity. These data indi-
cate that hTERT promoter methylation is a necessary event for 
hTERT expression, as is telomerase activity. However, methy-
lation is not sufficient for hTERT activation, particularly in 
normal colorectal cells.
Introduction
Telomerase activation is a critical step in human carcinogen-
esis to maintain the telomere length; however, the mechanisms 
for its activation and regulation remain to be determined. The 
expression of hTERT, the catalytic subunit of the telomerase 
enzyme, reveals a marked correlation to telomerase activity in 
tumors. In the majority of tumors, active telomerase requires 
the expression of hTERT. Furthermore, hTERT, which is tightly 
regulated, is not detectable in most somatic cells where telom-
erase activity is not present or is at basal level (1,2). hTERT 
expression may be regulated by various epigenetic factors, 
including promoter methylation or chromatin remodeling (3,4) 
and by activators and repressors such as C-Myc, Sp1, USF1/2, 
p53, TGF-β and CTCF (5-7).
One of the most crucial mechanisms by which hTERT 
expression is regulated occurs throughout DNA methylation 
in the hTERT promoter, which is embedded in a large CpG 
island. Hypermethylation of hTERT was found to be necessary 
for its expression in cancer cells (3,8). The apparent opposition 
to the classic model of regulation was recently clarified by the 
observation that methylation plays a dual role (9,10). hTERT 
methylation prevents the binding and thus the repressive effect 
of CTCF. However, a small hypomethylated region around the 
transcription start site allows a weak transcription of hTERT, 
despite the hypermethylation of the border regions. In most 
normal tissues, the telomerase activity is maintained at a 
basal level and it has been shown that these normal somatic 
cells have a hypomethylated promoter (3,11,12). Certain 
proliferative somatic cells, such as colorectal crypts as well 
as gastric and endometrial cells, revealed telomerase activity 
and hTERT expression concomitantly with the presence of 
hTERT methylation (3, JB, unpublished data). An increase 
of telomerase activity was observed in samples of normal, 
transitional and tumor mucosa from patients with sporadic 
colorectal cancer (13). Since in the colon hTERT methylation 
was detected in normal and tumor tissues, we aimed to 
investigate whether a relationship exists between the level of 
telomerase activity and the degree of hTERT promoter methy-
lation in colorectal tissues. Similarly, a potential relationship 
between hTERT promoter methylation and telomere length 
was also determined.
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Materials and methods
Tissue samples. This study involved 11 patients who under-
went surgery for colorectal cancer at the Lleida Arnau de 
Vilanova Hospital. Of the 11 patients, 7 were male and 4 were 
female and their average age was 75.40 years (range 65-82). 
Surgically resected samples of cancer tissue and transitional 
and normal mucosa were immediately frozen in liquid 
nitrogen and stored at -80˚C. The transitional mucosa was 
defined as having a macroscopically normal appearance and 
lying <1 cm away from the tumor, while the normal mucosa 
was obtained 10 cm away from the tumor. The research 
protocol was approved by the Hospital Clinic Research Ethics 
Committee of Lleida. Microdissection of two normal colon 
samples was performed as previously described in order to 
independently analyze the colon and stromal cells (14).
Fluorescent-telomeric repeat amplification protocol assay. 
Telomerase activity was measured using a quantitative system 
of the fluorescent‑telomeric repeat amplification protocol 
assay (TRAP-F), using a TRAPeze® telomerase detection kit 
(InterGen) (15). The analysis was performed as described in a 
previous study (13).
Telomere length measurement by Southern blotting. The 
telomere restriction fragment (TRF) length was determined 
by Southern blotting (Telo TAGGG Telomere length assay, 
Roche Diagnostics GmbH, Mannheim, Germany) in the 
tumor, transitional and normal tissues. The analysis was 
performed as previously described (16). The telomere length 
was expressed in kbp. The telomere length ratio (TLR) was 
determined as the quotient between the TL in the tumor 
tissue and the TL in normal mucosa from the same patient. 
Telomere shortening and elongation were defined as TLs of 
carcinoma <80% and >120% of the corresponding normal 
mucosa, respectively.
Methylation-sensitive single-strand conformation analysis 
(MS-SSCA). Bisulfite modification of 1 µg of genomic DNA (or 
10 ng of DNA extracted from microdissected normal tissues) 
was performed using the EpiTect® Bisulfite kit (Qiagen) 
according to the manufacturer's instructions. One twenty‑fifth 
of modified DNA was used to amplify a 220 bp fragment of 
the hTERT promoter (17). PCR products were analyzed by 
methylation-sensitive single-strand conformation analysis 
(MS-SSCA) as previously described (18).
Results
The methylation status of the hTERT promoter was analyzed, 
and the telomerase activity and telomere length were deter-
mined in normal, transitional and tumor samples from 
11 patients who underwent surgery for a sporadic colorectal 
cancer. The analysis of hTERT promoter methylation was 
performed by MS‑SSCA after bisulfite modification of 
genomic DNAs. Four cases are shown in Fig. 1. In all samples, 
a mixture of unmethylated and fully methylated alleles at 
varying ratios was observed. In cases 1 and 2, a significant 
difference in the level of hTERT methylation between tumor 
and normal tissues was detected. For example, in case 2, the 
level of methylation was approximately 70% in the tumor 
sample, whereas the methylation level reached only 40% in 
the transitional mucosa and only 10% in the normal mucosa. 
A similar level of methylation was observed in normal and 
tumor samples in cases 3 and 4. As shown in Table I, the mean 
level of hTERT methylation was higher in tumor samples 
(51%) compared with transitional (35%) and normal (20%) 
samples. After separation by microdissection of epithelial 
cells and stromal cells from two normal colon tissues, no 
methylation was detected in the hTERT promoter of stromal 
cells (data not shown). Therefore, the hTERT methylation 
observed in the normal colorectal tissues evidently originated 
from the colonic cells.
Figure 1. Analysis of the hTERT promoter methylation by MS-SSCA. Four representative cases, with tumor, transitional and normal mucosa, are shown. 
Square brackets indicate the migration of the unmethylated DNA (Unmethyl. CpGs) and the hypermethylated DNA (Methyl. CpGs). The percentage of 
methylated alleles is reflected by the ratio of intensity between the methylated and unmethylated bands. The percentage of methylation is shown under each 
sample. C, cancer tissue; T, transitional tissue; N, normal tissue. 0, 50 and 100% is the scale of methylation.
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Since all of the samples in this study contained at least 
40-50% of colorectal cells, it is evident that in a certain 
number of samples only a subset of colorectal cells (normal or 
tumoral) harbored a methylated hTERT promoter. Therefore, 
in order to avoid insignificant methylation levels, a low level 
of hTERT methylation was arbitrarily considered when the 
percentage of methylation was <25%. As shown in Table II, 
the samples were divided into two categories: low level 
(<25%) and high level (≥25%) of methylation. In tumors, all 
but one of the samples exhibited a high level of methylation. 
The percentage of cases with a high level of methylation 
decreased to 73% in transitional samples, and 36% in normal 
samples. 
The mean telomerase activity was 40-80 times higher 
in tumor samples than in transitional and normal mucosa, 
respectively, whereas the mean level of hTERT methylation 
was only 1.5-2.5 times higher in tumor samples (Table I). 
In normal and transitional tissues, a low level of telomerase 
activity was observed even in the presence of a high level of 
methylation (Table III).
A reduction in the mean telomere length was observed 
between normal (9 kbp), transitional (8.82 kbp), and tumor 
mucosa (7.66 kbp) (Table I). These results confirmed that 
tumor cells have shorter telomeres compared to normal cells 
(19). Notably, in the tumor, transitional and normal samples, 
the mean telomere length was always shorter in the samples 
with a low level of methylation than in those with a high level 
of methylation (Table III).
An increase of hTERT methylation and telomerase 
activity, and a reduction of mean telomere length were 
observed in the transitional mucosa in comparison to the 
distant normal mucosa. However, the significant increase of 
methylation in the transitional tissues was not concomitant 
with high telomerase activity, as observed in the tumor 
samples (Tables II and III). These data indicate that hTERT 
promoter methylation is not linearly correlated to telomerase 
activity in colorectal tissues.
Discussion
A significant increase of hTERT methylation and telome‑
rase activity, and a reduction of mean telomere length were 
observed from normal to tumor tissue. This observation also 
proves to be true of transitional to tumor mucosa, but to a 
lesser extent. A correlation between the degree of methylation 
and telomerase activity was found in colorectal tumor samples. 
Table I. Mean age, methylation rate, telomerase activity and 
telomere length in tumor, transitional and normal mucosa.
Characteristics Mean Range
Age 75.4 years 65-82 years
Methylation rate
  Tumor mucosa 51% 10-100%
  Transitional mucosa 35% 10-50%
  Normal mucosa 20% 5-40%
Telomerase activity
  Tumor mucosa 44.20 0-164
  Transitional mucosa 1.12 0-8
  Normal mucosa 0.53 0-3
Telomere length
  Tumor mucosa 7.66 kbp 5.66-10.64 kbp
  Transitional mucosa 8.82 kbp 6.80-10.95 kbp
  Normal mucosa 9 kbp 6.99-11.02 kbp
The telomerase activity was measured in arbitrary units.
Table II. Low and high level of hTERT methylation in tumor 
and normal colorectal tissues.
 Met <25 (%) Met ≥25 (%) Total (%)
Tumor mucosa
  TA- 0 (0)  2 (18) 2 (18)
  TA+ 1 (9)  8 (73) 9 (82)
  Total 1 (9) 10 (91) 11 (100)
Transitional mucosa
  TA-   2 (18)  3 (27) 5 (45)
  TA+ 1 (9)  5 (46) 6 (55)
  Total   3 (27)  8 (73) 11 (100)
Normal mucosa
  TA-   4 (36)   3 (27) 7 (64)
  TA+   3 (27) 1 (9) 4 (36)
  Total   7 (64)   4 (36) 11(100)
The level is considered as low when the percentage of hTERT methyl 
ation (Met) was <25% and as high when the percentage was >25%. 
Telomerase activity was measured in arbitrary units. Met, hTERT 
methylation; TA, telomerase activity.
Table III. Means of telomerase activity and telomere length in 
tumor and normal colorectal tissues according to the degree of 
hTERT methylation.
 Met <25% Met ≥25%
Tumor mucosa
  Telomerase activity 15 47.1
  Telomere length 5.66 kpb 7.87 kpb
Transitional mucosa
  Telomerase activity 0.13 1.75
  Telomere length 7.31 kpb 8.46 kpb
Normal mucosa
  Telomerase activity 0.40 0.75
  Telomere length 8.55 kpb 9.69 kpb
The level was considered as low when the percentage of hTERT 
methylation (Met) was <25%, and as high when the percentage was 
>25%. Telomerase activity was measured in arbitrary units.
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In other words, tumors with a high degree of hTERT methyla-
tion revealed high telomerase activity. An apparently different 
behavior occurred in transitional and normal mucosa: the 
telomerase activity was low in the two cases regardless of 
the methylation status of the hTERT promoter. Nevertheless, 
when the level of hTERT methylation was high, a higher level 
of telomerase activity was observed in transitional and normal 
samples. Therefore, in tumor and normal tissues, the higher the 
number of colorectal cells harboring an hTERT methylated 
promoter, the more significant the level of telomerase activity.
This study showed that hTERT promoter methylation is 
required for hTERT expression, and thus telomerase activity, 
but it is not sufficient to allow hTERT expression in normal 
colorectal cells. The data observed in this study are in accor-
dance with those previously obtained in in vitro transcription 
experiments with hTERT reporter gene constructs. The tran-
scriptional activity of the hTERT core promoter was found 
to be significantly higher in cancer cells than in normal cells 
(9). Considering the significance of this enzyme, it is clear 
that other factors should be recruited to modulate hTERT 
expression.
hTERT methylation detected in normal mucosa may come 
from the few stem cells and more largely from the daughter 
stem cells, known as niche cells, contained in the colorectal 
crypts. In previous studies, the cell expression of hTERT 
determined by immunohistochemistry indicated that hTERT 
is mainly expressed at the base of the crypts (20). The fact 
that hTERT in transitional mucosa was more methylated than 
in normal mucosa (mean of 35 versus 20%) indicates that 
some significant changes occur in normal colorectal cells in 
the vicinity of a tumor. This phenomenon may be due either 
to high cell renewal or to the occurrence of epigenetic modi-
fications in the colorectal cells close to a cancer. Aberrant 
methylation of CpG island promoters is known to be an early 
event in colorectal carcinogenesis (21). Therefore, a favorable 
hTERT methylation context may initiate the first phase of 
carcinogenesis.
hTERT methylation was related, to a certain extent, to the 
telomerase activity in normal and tumor colorectal tissues. 
Low but significant levels of hTERT methylation and weak 
telomerase activity are already present in the normal colorectal 
cells. A slight increase of hTERT methylation, concomitantly 
with a great change in telomerase activity level, occurs in 
tumor cells. In conclusion, this study indicates that hTERT 
promoter methylation is required but not sufficient for hTERT 
expression and telomerase activity in colorectal cells.
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